U.K. Watchdog Says GSK Infringed Competition Law With “Pay-For-Delay” Deals
This article was originally published in The Pink Sheet Daily
The U.K.'s Office of Fair Trading is proceeding with its action against GlaxoSmithKline, alleging it held back generic competition to its best-selling antidepressant paroxetine from 2001 to 2004 through agreements with generic drug firms.
You may also be interested in...
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.